CMS Reports: Cost-Effectiveness of Screening Tests for Colorectal Cancer

These efforts were undertaken as a joint effort between multiple CISNET groups and US Government health policy makers which resulted in three reports to Centers for Medicare and Medicaid Services (CMS). One is a cost-effectiveness analysis of CT colonography, completed in 2009. Another is a cost-effectiveness analysis for the new stool DNA test, completed in 2007. The third is a cost-effectiveness analysis for the new immunochemical fecal occult blood tests (FOBT), completed in 2003.

Cost-Effectiveness of CT Colonography to Screen for Colorectal Cancer

CISNET members from Memorial Sloan-Kettering, University of Minnesota, Group Health Research Institute, and Erasmus MC worked together on the following report.

Zauber AG, Knudsen AB, Rutter CM, Lansdorp-Vogelaar I, Savarino JE, van Ballegooijen M, Kuntz KM. Cost-Effectiveness of CT Colonography to Screen for Colorectal Cancer: Report to the Agency for Healthcare Research and Quality from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN, SimCRC, and CRC-SPIN Models. January 22, 2009. Available from: https://www.cms.gov/medicare-coverage-database/view/technology-assessments.aspx?TAId=58

Cost-Effectiveness of DNA Stool Testing to Screen for Colorectal Cancer

CISNET members from Harvard School of Public Health, Memorial Sloan-Kettering, and Erasmus MC worked together on the following report.

Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM. Cost-effectiveness of DNA stool testing to screen for colorectal cancer: Report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models. December 20, 2007. Available from: https://www.cms.gov/medicare-coverage-database/search.aspx?redirect=Y&from=Overview&where=index&tid=52

Cost-Effectiveness of the Immunochemical Fecal Occult Blood Tests

CISNET members from Erasmus University and Memorial Sloan-Kettering worked together with NCI on the following report.

van Ballegooijen M, Habbema JDF, Boer R, Zauber AG, Brown ML. Report to the Agency for Healthcare Research and Quality: a comparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population. August, 2003. Available from: https://www.cms.gov/medicare-coverage-database/view/technology-assessments.aspx?TAId=20